
An essential structural feature of the new compounds is the 6-oxo-1,6-dihydro-pyridazine-4-carboxylic acid amide group that is present in tautomeric equilibrium with the 6-hydroxy-pyridazine-4-carboxylic acid amide group:



Compared with the compounds from the prior art, the new substances are characterised in that they exhibit a strong B1-receptor blocking activity and at the same time have improved metabolic stability.


SUMMARY

In a first aspect, there is provided compounds of general formula I



, (I)

wherein

R^1 denotes the group ,

R^2 denotes H or CH_3,

R^3 and R^4 together with the carbon atom to which they are bound denote a C_{3-6}-cycloalkylene group wherein a $-CH_2$ unit may be replaced by an oxygen atom,

R^5 denotes H or CH_3,

R^6 denotes H, F, Cl or methyl,

R^7 denotes H, F, Cl, Br, -CN, C_{1-4}-alkyl, CF_3, CHF_2,

R^8 denotes H,

R^9 denotes F, Cl, Br, C_{1-4}-alkyl, -O-C_{1-4}-alkyl, -S-C_{1-4}-alkyl,

R^{10} denotes H,

R^{11} denotes F, Cl, Br, -CN, C_{1-4}-alkyl, CF_3, CHF_2, and

X denotes CH or N,

the enantiomers, the diastereomers, the mixtures and the salts thereof.

In a second aspect, there is provided physiologically acceptable salts of the compounds as defined above with inorganic or organic acids or bases.

In a third aspect, there is provided medicaments, containing a compound as defined above or a physiologically acceptable salt as defined above optionally together with one or more inert carriers and/or diluents.

In a fourth aspect, there is provided a compound of general formula I as defined above for use as medicaments.


In a fifth aspect, there is provided a compound of general formula I as defined above for preparing a medicament for the acute and prophylactic treatment of acute pain, visceral pain, neuropathic pain, inflammatory / pain receptor-mediated pain, tumour pain and headache diseases.

In a sixth aspect, there is provided the use of a compound as defined above for preparing a medicament for the acute and prophylactic treatment of osteoarthritis.

In a seventh aspect, there is provided a process for preparing a medicament as defined above, characterised in that a compound as defined above is incorporated in one or more inert carriers and/or diluents by a non-chemical method.

DETAILED DESCRIPTION OF THE INVENTION

In the above general formula I in one embodiment 1

R^1 denotes the group ,

R^2 denotes H or CH_3,

R^3 and R^4 together with the carbon atom to which they are bound denote a C_{3-6}-cycloalkylene group wherein a $-CH_2$ unit may be replaced by an oxygen atom,

R^5 denotes H or CH_3,

R^6 denotes H, F, Cl or methyl,

R^7 denotes H, F, Cl, Br, -CN, C_{1-4}-alkyl, CF_3, CHF_2,

R^8 denotes H,

R^9 denotes F, Cl, Br, C_{1-4}-alkyl, -O-C_{1-4}-alkyl, -S-C_{1-4}-alkyl,